IMPORTANCE Treatment of pityriasis rubra pilaris (PRP) is solely based on its resemblance to psoriasis rather than any knowledge of its pathomechanism. Insight into pathogenic mediators of inflammation is essential for targeted and valid treatment options that could replace previous serendipitous therapeutic approaches in refractory PRP.
P ityriasis rubra pilaris (PRP) is a chronic inflammatory skin disease that typically appears sporadically and is acquired in most cases. 1 Pityriasis rubra pilaris is clinically characterized by follicular hyperkeratosis on an erythematous base. These papules show a tendency to coalesce, thereby forming large orange-red plaques with classic demarcated islands of sparing. Pityriasis rubra pilaris frequently involves the palms and soles, leading to palmoplantar orange-red waxy keratoderma. The major clinical differential diagnosis is psoriasis. However, in its most common form, type 1 PRP is typically self-limited and resolves within 3 years in 80% of cases. Based on reported associations with various autoimmune diseases, such as myasthenia gravis, arthritis, and myositis, a pathogenesis driven by an aberrant immune response has been suggested. However, the pathogenesis of PRP remains elusive. Thus, treatment of PRP is mainly empirical and, owing to its resemblance to psoriasis, classic treatments for psoria- 
μm
A, Clinical image of a patient in his 40s with PRP shows typical orange-red follicular papules with scaly centers progressing to a widespread suberythroderma with islands of normal skin. B, Histopathologic evaluation of lesional skin with PRP shows a psoriasiform acanthosis (thickening of the epidermis), irregular hyperkeratosis (thickening of the corneal layer) with alternating vertical and horizontal orthokeratosis and parakeratosis (characteristic checkerboard pattern), and keratin plugs in the follicles (hematoxylin-eosin, bar indicates 100 μm these treatments was based on a pathophysiological rationale, but solely on the resemblance of PRP to psoriasis. Herein we report that the cytokine expression in PRP shows a helper T cell 17 (T H 17) and T H 1 profile and that clinical improvement parallels the decrease in lesional T H 17 cytokines during effective anti-IL-12/IL-23 therapy. These findings suggest a role for T H 17 cytokines in PRP and provide basis for a targeted treatment in blocking the IL-23-T H 17 axis.
Methods
Skin biopsy samples were obtained from 3 patients with PRP at specified time points. Skin samples were fixed using 4% paraformaldehyde for histopathologic analysis or snap frozen and stored at −80°C for reverse transcription-polymerase chain reaction analysis (RT-PCR). Paraffin-embedded skin sections were deparaffinized and stained using a standard hematoxylin-eosin staining protocol. For quantitative RT-PCR, complementary DNA was synthesized using reverse transcriptase (SuperScript II; Invitrogen), and relative gene expression was quantified using specific probes (TaqMan; Life Technologies) and calculated using the comparative C T method, where 2 Δ-ΔCt describes the differ- 
Report of a Case
A man in his 40s with PRP presented with painful palmoplantar hyperkeratosis, erythema of the face and scalp, and characteristic confluent red to orange follicular papules progressing to suberythroderma ( Figure 1A ). Diagnosis was confirmed by results of histopathologic analysis showing a psoriasiform dermatitis with irregular hyperkeratosis and the typical alternating vertical and horizontal orthokeratosis and parakeratosis (checkerboard pattern), keratin plugs in the follicles, and a sparse lymphohistiocytic, perivascular dermal infiltrate ( Figure 1B ). Because PRP shares common features with psoriasis, we analyzed messenger RNA (mRNA) expression of innate and adaptive cytokines involved in psoriasis pathogenesis. We found upregulated mRNA expression levels for most proinflammatory innate cytokines, including TNF, IL-6, IL-12, IL-23, and IL-1β in the lesional skin sample of the patient with PRP compared with normal skin ( Figure 1C ). Among adaptive T-cell cytokines, we found a particular increase of T H 17 cytokines IL-17A, IL-17F, and IL-22 in PRP compared with basal expression in normal skin, suggesting that these cytokines might play a pathogenic role in PRP similar to that in psoriasis. Preferential overexpression of T H 17 cytokines was confirmed in 2 additional patients with PRP, showing a similar profile ( Figure 2) . Furthermore, cytokines of the IL-23-T H 17 axis showed comparable mRNA expression levels in all 3 patients with PRP and in psoriasis. 
IL-22
Messenger RNA (mRNA) expression of innate cytokines and adaptive T-cell-derived cytokines in the lesional skin samples of 3 patients (the patient in Figure 1 and 2 additional patients) with PRP compared with healthy skin (HS) confirms upregulation of proinflammatory innate cytokines and T H 17 cytokines in PRP. Triangles represent individual donor with HS; dots, individual patients with PRP (open symbol corresponds to the patient in Figure 1 ). Horizontal bar denotes the mean value. IFN-γ indicates interferon-γ; IL, interleukin; and TNF, tumor necrosis factor.
Research Brief Report Anti-Interleukin 23 as a Targeted Treatment Option for Pityriasis Rubra Pilaris
In our patient, topical therapies remained insufficient; his PRP was further aggravated despite 4 months of treatment. Worsening of the dermatosis on sun exposure prevented us from using phototherapy. Acitretin and methotrexate were contraindicated owing to a history of a drug-induced hepatitis with ongoing elevation of liver enzyme levels. Because IL-23 is critical for the differentiation and expansion of T H 17 cells, 5, 6 and because we found a preferential overexpression of T H 17 cytokines, we opted for ustekinumab (Stelara), a human anti-IL-12/IL-23 antibody approved for severe psoriasis. 7 Subcutaneous ustekinumab, 45 mg, was given at weeks 0 and 4 and quarterly thereafter, according to the psoriasis dose regimen. The lesions showed regression after 2 weeks and almost complete resolution after 1 month ( Figure 3A) . After 6 months, the treatment was interrupted and the patient remained in remission. The clinical improvement as reflected by the 4-point Physician Global Assessment (a measure of the mean redness, thickness, and scaling of the lesions, each graded on a scale of 0-4, with higher scores indicating increased severity) nicely paralleled the mRNA expression of IL-17A and IL-17F and, to some degree, expression of IL-22 ( Figure 3B ). On the other hand, although the expression of TNF and IFN-γ declined eventually, their decrease markedly lagged behind the clinical improvement, whereas IL-1β and IL-10 mRNA expression remained unchanged after 6 months of treatment. Furthermore, the expression of T H 17 cytokines also paralleled the improvement of histopathologic findings, such as normalization of the epidermal thickening and the corneal layer and attenuation of the cellular infiltrate ( Figure 3C ). This finding suggests a role for T H 17 cytokines in the pathogenesis of PRP and in driving its skin phenotype.
Discussion
Studies of PRP treatment are hampered by the unclear pathogenesis and the low incidence of the disease; therefore PRP therapy is based on the results of small case series and case reports. 8, 9 Consequently, the therapy for PRP remains largely perproliferation and altered differentiation of keratinocytes are also hallmarks of PRP, rendering T H 17 cells an interesting therapeutic target in PRP. Indeed, we found an increased T H 17 expression profile in skin lesions of 3 patients with PRP and showed that the expression levels of T H 17 cytokines, but not of TNF or the T H 1 cytokine IFN-γ, paralleled clinical improvement during anti-IL-12/IL-23 treatment. Pityriasis rubra pilaris is often self-limiting, but the progressive disease course before treatment and the rapid response after a single injection strongly suggest that disease resolution was not spontaneous. Furthermore, previous reports in PRP described equally rapid efficacy on initiation of ustekinumab treatment.
3 Successful anti-IL-17 treatment of a patient with refractory PRP was also recently reported, which further supports an efficacy of the IL-23-T H 17 blockade in PRP.
14 This study indicates a shared inflammatory pathway in psoriasis and PRP. Interestingly, mutations in the caspase recruitment domain family member 14 gene (CARD14 [HGNC 16446]) have been identified in both diseases, raising the possibility that CARD14 is upstream of the IL-23-T H 17 pathway. However, our patient did not display any CARD14 mutation known in familial 15 or sporadic 16 PRP. Whether the efficacy of blocking the IL-23-T H 17 pathway is linked to a specific genotype and/or clinical subtype remains to be shown. Despite pathogenic commonalities between psoriasis and PRP, obvious distinctions remain, such as orange-red waxy keratoderma, follicular hyperkeratosis, and absence of neutrophils in PRP. Future studies should identify pathologic mechanisms underlying these differences. Another feature of PRP is its spontaneous resolution. Interestingly, we found higher levels of IL-10 in PRP compared with psoriasis, which persisted on treatment, suggesting a potential antiinflammatory pathway in PRP.
Limitations
This study has some limitations owing to the restricted number of patients included. Additional studies will need to further corroborate our findings by treating larger cohorts of patients with PRP using ustekinumab, and anti-IL-17-and anti-IL-23-specific antibodies.
Conclusions
This study identifies a role of the IL-23-T H 17-axis in PRP, suggesting a shared pathogenic inflammatory pathway with psoriasis. The findings provide a rationale for targeting the IL-23-T H 17 axis as a treatment option for refractory PRP that could replace previous serendipitous therapeutic approaches.
